2019-2020

UMB Phased Research Plan: Stage 1 of Clinical and Community-Based Human Subjects Research

• During the Stage 1 phase, we will continue minimal-risk studies that are remote or no contact.  

• Research (including community-based research) that has the potential for direct benefit to the research subject and requires in-person visits at UMB-related facilities may be resumed upon approval of the UMB Environmental Health and Safety Checklist for Resuming Clinical Research and the Operations Assessment Tool by UMB’s Institutional Review Board (IRB). Documentation must be submitted through the Reportable New Information pathway in CICERO. The forms can be found on the Human Research Protections Office website.  

• If Stage 1 goes as planned, we will begin the expanded research phase, labeled Stage 2, two weeks later Aug. 3, 2020. Stage 2 continues to allow minimal-risk studies and studies with the potential for direct benefits to the research subject that require in-person visits at UMB-related facilities. Stage 2 also allows for the resumption of studies that do not have the potential for direct benefit to the research subjects requiring in-person visits at UMB-related facilities. This includes interventional studies with no therapeutic intent, screening/diagnostic, and observational studies.